remaining obligations to symphony icon telecast data presented at the 2016 north american neuroendocrine tumor society annual symposium webcast baml global healthcare conference fda extends pdufa date for telotristat etiprate for the treatment of carcinoid syndrome webcast intandem1 phase 3 top line results precisionscience pioneeringmedicine patientdriven previous next lexicon pharmaceuticals announces agreement to buy out remaining obligations to symphony icon telecast data presented at the 2016 north american neuroendocrine tumor society annual symposium webcast baml global healthcare conference fda extends pdufa date for telotristat etiprate for the treatment of carcinoid syndrome webcast intandem1 phase 3 top line results telotristat etiprate lx1032 an orally delivered small molecule compound developed for the treatment of carcinoid syndrome . read more sotagliflozin lx4211 an orally delivered small molecule compound that we are developing for the treatment of type 1 and type 2 diabetes . read more about us we are a biopharmaceutical company focused on the development of breakthrough treatments for human disease.read more careers at lexicon our passion and dedication is driven by the patients we work for . come be a part of our multitalented team . read more precision science pioneering medicine patient driven thank you for your interest . your e mail will be added to our list for news alerts . sorry our system is unable to handle this right now . please contact us directly . homeabout uspipelinecollaborationsinvestorsmedia centereventscareers copyright 2016 lexicon pharmaceuticals inc. all rights reserved policiesterms of usecontact ussitemap